OOIR: Observatory of International Research

Papers

(The H4-Index of Biomarker Research is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Metabolic reprogramming in macrophage responses	261
Biomarkers for cancer-associated fibroblasts	167
miR-21: a non‐specific biomarker of all maladies	144
Recent advances in systemic therapy for hepatocellular carcinoma	116
The landscape of bispecific T cell engager in cancer treatment	114
Targeting ferroptosis in breast cancer	104
CAR-NK cells for cancer immunotherapy: from bench to bedside	94
A comprehensive comparison between camelid nanobodies and single chain variable fragments	93
Biological roles of RNA m5C modification and its implications in Cancer immunotherapy	87
Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study	78
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion	74
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy	73
Imaging biomarkers for evaluating tumor response: RECIST and beyond	69
Nanobody-based CAR-T cells for cancer immunotherapy	66
Blood biomarkers for mild traumatic brain injury: a selective review of unresolved issues	65
Detection of circulating tumor cells: opportunities and challenges	64
Immune cells-derived exosomes function as a double-edged sword: role in disease progression and their therapeutic applications	62
Immunotherapy in endometrial cancer: rationale, practice and perspectives	62
Alternative Polyadenylation: a new frontier in post transcriptional regulation	60
Anti-Mesothelin CAR T cell therapy for malignant mesothelioma	57
The role of ferroptosis in lung cancer	57
Cancer-associated adipocytes as immunomodulators in cancer	53
Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment	53
Structures and biological functions of zinc finger proteins and their roles in hepatocellular carcinoma	52
The role of biomarkers in personalized immunotherapy	51

Targeting interleukin-1β and inflammation in lung cancer	50
Prolonged elevation of serum neurofilament light after concussion in male Australian football players	49
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy	49
Temporal trend of gastric cancer burden along with its risk factors in China from 1990 to 2019, and projections until 2030: comparison with Japan, South Korea, and Mongolia	48
p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors	47
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis	46
The role of phosphatidylserine on the membrane in immunity and blood coagulation	46
Risk factors for immune-related adverse events: what have we learned and what lies ahead?	44
Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed	42
The landscape overview of CD47-based immunotherapy for hematological malignancies	41
TOX as a potential target for immunotherapy in lymphocytic malignancies	39
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives	38
Intratumor microbiome in cancer progression: current developments, challenges and future trends	38
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives	38